A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease.

Trial Profile

A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease; Dyspnoea
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW-1
  • Sponsors Novartis
  • Most Recent Events

    • 23 Oct 2012 Planned number of patients changed from 800 to 1230.
    • 05 Sep 2012 Results from a pooled analysis of GLOW 1 and GLOW 2 presented at the 22nd Annual Congress of the European Respiratory Society.
    • 03 Sep 2012 Results from pooled analyses of GLOW-1 and GLOW-2 have been presented at the 2012 Annual Congress of the European Society of Cardiology (ESC-2012) according to a Novartis media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top